Jordi M. Anton

Barcelona, CT, ES

Expertise in

conditions

Barcelona, CT, ES

OverviewLocationsClinical Research

Overview

Jordi Anton practices in Barcelona, Spain. Anton is highly rated in 33 conditions, according to our data. Their top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Mevalonate Kinase Deficiency, Scleroderma, Kawasaki Disease, and Bone Marrow Aspiration.

Their clinical research consists of co-authoring 153 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Barcelona, CT, Spain

Other Locations

Esplugues De Llobregat, CT, Spain

Vilafranca Del Penedes, CT, Spain

Sant Joan, PM, Spain

Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Enrollment Status: Active_not_recruiting

Publish Date: June 05, 2025

Intervention Type: Drug

Study Drugs: Ixekizumab, Adalimumab

Study Phase: Phase 3

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes

Enrollment Status: Unknown

Publish Date: November 30, 2023

A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

Enrollment Status: Completed

Publish Date: June 28, 2022

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Enrollment Status: Completed

Publish Date: May 17, 2022

Intervention Type: Drug

Study Drug: Emapalumab Anti-IFN-Gamma Antibody

Study Phase: Phase 2

View 3 Less Clinical Trials

152 Total Publications

Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach.

Journal: Expert opinion on biological therapy

Published: October 18, 2025

View All 152 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Anton's expertise for a condition

ConditionClose